By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084



Company News
Advaxis, Inc. Appoints Fred J. Frullo Vice President, Regulatory Affairs 5/21/2015 11:35:28 AM
Advaxis, Inc. And Sorrento Form Collaboration To Evaluate Combinations Of Advaxis's Lm-LLO Immunotherapy Technology And Sorrento's Immunomodulatory Antibodies 5/19/2015 8:20:15 AM
Advaxis, Inc. Appoints Thomas W. Hare Vice President, Clinical Operations 5/6/2015 8:31:30 AM
Advaxis, Inc. Announces Closing Public Offering Of Common Stock With Gross Proceeds Totaling $53.2 Million 5/6/2015 8:25:30 AM
Advaxis, Inc. Prices $53 Million Public Offering Of Common Stock 4/30/2015 7:43:09 AM
Advaxis, Inc. Announces Proposed Public Offering Of Common Stock 4/30/2015 7:24:54 AM
Advaxis, Inc. Enhances Lm-LLO Cancer Immunotherapy Intellectual Property Portfolio With Two USPTO Patents Addressing ADXS-PSA And ADXS-HER2 4/28/2015 7:45:11 AM
Advaxis, Inc. Presents Lm-LLO Cancer Immunotherapy Data at the 2015 AACR Meeting 4/21/2015 4:42:03 PM
Advaxis, Inc. Included Among "25 Top Immunotherapy Companies" In Newly Launched Loncar Cancer Immunotherapy Index (LCINDX) 4/10/2015 8:42:44 AM
Advaxis, Inc. And Merck & Co. (MRK) Announce Initiation Of Enrollment In The Phase I/II Study Of ADXS-PSA In Combination With Anti-PD-1 Therapy, KEYTRUDA (Pembrolizumab), For The Treatment Of Advanced Prostate Cancer 4/8/2015 7:15:53 AM